Neoadjuvant ICI Without Chemotherapy Demonstrates Potential Efficacy in Patients with Early-Stage TNBC By Ogkologos - November 21, 2024 941 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BELLINI study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Are differences in treatment driving variation in ovarian cancer survival internationally? August 11, 2020 Best Friends and Owners of a Specialty Cheese Shop Battle Breast... June 11, 2021 What Are Multi-Cancer Early Detection Tests and How Might They Impact... October 25, 2022 Selpercatinib Shows Durable Efficacy in RET-Altered Thyroid Cancer August 28, 2020 Load more HOT NEWS Five-Year Follow-up of Adjuvant Dabrafenib plus Trametinib in Resected Stage III... FDA Grants Accelerated Approval to Tucatinib with Trastuzumab for Colorectal Cancer Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy,... Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients...
